554 related articles for article (PubMed ID: 18666036)
1. Daptomycin, a lipopeptide antibiotic in clinical practice.
Weis F; Beiras-Fernandez A; Schelling G
Curr Opin Investig Drugs; 2008 Aug; 9(8):879-84. PubMed ID: 18666036
[TBL] [Abstract][Full Text] [Related]
2. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
Steenbergen JN; Alder J; Thorne GM; Tally FP
J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
Rybak MJ
Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721
[TBL] [Abstract][Full Text] [Related]
4. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
Carpenter CF; Chambers HF
Clin Infect Dis; 2004 Apr; 38(7):994-1000. PubMed ID: 15034832
[TBL] [Abstract][Full Text] [Related]
5. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.
Kanafani ZA; Corey GR
Expert Rev Anti Infect Ther; 2007 Apr; 5(2):177-84. PubMed ID: 17402833
[TBL] [Abstract][Full Text] [Related]
6. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci.
Cervera C; Castañeda X; Pericas JM; Del Río A; de la Maria CG; Mestres C; Falces C; Marco F; Moreno A; Miró JM
Int J Antimicrob Agents; 2011 Nov; 38(5):365-70. PubMed ID: 21420835
[TBL] [Abstract][Full Text] [Related]
8. The use of daptomycin for Staphylococcus aureus infections in critical care medicine.
Alder J
Crit Care Clin; 2008 Apr; 24(2):349-63, ix-x. PubMed ID: 18361950
[TBL] [Abstract][Full Text] [Related]
9. [Daptomycin: revitalizing a former drug due to the need of new active agents against grampositive multiresistant bacterias].
Hernández Martí V; Romá Sánchez E; Salavert Lletí M; Bosó Ribelles V; Poveda Andrés JL
Rev Esp Quimioter; 2007 Sep; 20(3):261-76. PubMed ID: 18080024
[TBL] [Abstract][Full Text] [Related]
10. [The second life of daptomycin: analysis of a successful come-back].
Decousser JW; Doucet Populaire F
Med Mal Infect; 2008 Dec; 38 Spec No 2():1-3. PubMed ID: 19185200
[No Abstract] [Full Text] [Related]
11. [Daptomycin--a new antibiotic for the treatment of skin and soft tissue infections].
Mathiesen L; Midtvedt T; Solberg CO
Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2383-4. PubMed ID: 16998552
[TBL] [Abstract][Full Text] [Related]
12. Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin.
French GL
J Antimicrob Chemother; 2006 Dec; 58(6):1107-17. PubMed ID: 17040922
[TBL] [Abstract][Full Text] [Related]
13. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin.
Skiest DJ
J Clin Microbiol; 2006 Feb; 44(2):655-6. PubMed ID: 16455939
[TBL] [Abstract][Full Text] [Related]
14. Daptomycin: a review 4 years after first approval.
Sauermann R; Rothenburger M; Graninger W; Joukhadar C
Pharmacology; 2008; 81(2):79-91. PubMed ID: 17940348
[TBL] [Abstract][Full Text] [Related]
15. Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria.
Johnson A
Future Microbiol; 2006 Oct; 1(3):255-65. PubMed ID: 17661638
[TBL] [Abstract][Full Text] [Related]
16. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient].
Garnacho-Montero J; Amaya-Villar R; Gómez-Grande ML; Jerez V; Lorente-Ramos L; Loza A; Martínez A; Pozo JC; Sierra R; Pomares J; de la Torre MV; Ortiz C
Rev Esp Quimioter; 2011 Mar; 24(1):13-24. PubMed ID: 21412665
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry.
Martone WJ; Lamp KC
Curr Med Res Opin; 2006 Dec; 22(12):2337-43. PubMed ID: 17257448
[TBL] [Abstract][Full Text] [Related]
18. Daptomycin: rationale and role in the management of skin and soft tissue infections.
Seaton RA
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii15-23. PubMed ID: 18829721
[TBL] [Abstract][Full Text] [Related]
19. New drugs for Gram-positive uropathogens.
Wagenlehner FM; Naber KG
Int J Antimicrob Agents; 2004 Sep; 24 Suppl 1():S39-43. PubMed ID: 15364305
[TBL] [Abstract][Full Text] [Related]
20. Daptomycin.
Enoch DA; Bygott JM; Daly ML; Karas JA
J Infect; 2007 Sep; 55(3):205-13. PubMed ID: 17629567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
